Perceptive Advisors, a major life sciences investor, exited its entire position in Centessa Pharmaceuticals during the second quarter of 2026, according to a recent SEC filing. The firm sold all 5.26 million of its shares, which were valued at approximately $208.88 million at the end of March and represented a 4.08% portfolio weight.
Investors should note that 13F filings reflect trades from the previous quarter and are not indicative of current holdings. This particular exit coincides with the acquisition of Centessa by Eli Lilly, which was announced on March 31, 2026, and was expected to be completed during the third quarter. [3, 5] The sale was likely a result of Perceptive tendering its shares as part of the acquisition agreement.